The first synthetic agonists of FFA2: Discovery and SAR of phenylacetamides as allosteric modulators

Bioorganic and Medicinal Chemistry Letters

Volumn 20, Issue 2, 2010, Pages 493-498

  Wang, Yingcai ^a   Jiao, Xianyun ^a   Kayser, Frank ^a   Liu, Jiwen ^a   Wang, Zhongyu ^a   Wanska, Malgorzata ^a   Greenberg, Joanne ^a   Weiszmann, Jennifer ^a   Ge, Hongfei ^a   Tian, Hui ^a   Wong, Simon ^a   Schwandner, Ralf ^b   Lee, Taeweon ^a   Li, Yang ^a  

^a AMGEN INC   (United States)

^b Amgen Research GmbH   (Germany)

Author keywords

Agonist; Allosteric; FFA2; GPR43; Phenylacetamide

Indexed keywords

ACETANILIDE DERIVATIVE; ACETIC ACID; FATTY ACID; FREE FATTY ACID RECEPTOR 2 AGONIST; UNCLASSIFIED DRUG;

ADIPOCYTE; ALLOSTERISM; ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CELL STRAIN 3T3; CHO CELL; CONTROLLED STUDY; DRUG CLEARANCE; DRUG RECEPTOR BINDING; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; FATTY ACID BLOOD LEVEL; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; IN VIVO STUDY; LIPOLYSIS; LIVER MICROSOME; MALE; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION;

ACETAMIDES; ALLOSTERIC REGULATION; ANIMALS; CYCLIC AMP; DRUG DISCOVERY; HUMANS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; RATS; RECEPTORS, CELL SURFACE; RECEPTORS, G-PROTEIN-COUPLED; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 72249086955     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.11.112     Document Type: Article

References (28)

1. Covington D.K., Briscoe C.A., Brown A.J., and Jayawickreme C.K. Biochem. Soc. Trans. 34 (2006) 770
2. Stoddart L.A., Smith N.J., and Milligan G. Pharmacol. Rev. 60 (2008) 405
3. Sawzdargo M., George S.R., Nguyen T., Xu S., Kolakowski L.F., and O'Dowd B.F. Biochem. Biophys. Res. Commun. 239 (1997) 543
4. Rayasam G.V., Tulasi V.K., Davis J.A., and Bansal V.S. Expert Opin. Ther. Targets 11 (2007) 661
5. Brown A.J., Goldsworthy S.M., Barnes A.A., Eilert M.M., Tcheang L., Daniels D., Muir A.I., Wigglesworth M.J., Kinghorn I., Fraser N.J., Pike N.B., Strum J.C., Steplewski K.M., Murdock P.R., Holder J.C., Marshall F.H., Szekeres P.G., Wilson S., Ignar D.M., Foord S.M., Wise A., and Dowell S.J. J. Biol. Chem. 278 (2003) 11312
6. Le Poul E., Loison C., Struyf S., Springael J.Y., Lannoy V., Decobecq M.E., Brezillon S., Dupriez V., Vassart G., Van Damme J., Parmentier M., and Detheux M. J. Biol. Chem. 278 (2003) 25481
7. Nilsson N.E., Kotarsky K., Owman C., and Olde B. Biochem. Biophys. Res. Commun. 303 (2003) 1047
8. Wise A., Jupe S.C., and Rees S. Annu. Rev. Pharmacol. Toxicol. 44 (2004) 43
9. Lundstrom K. Curr. Protein Pept. Sci. 7 (2006) 465
10. Hong Y.H., Nishimura Y., Hishikawa D., Tsuzuki H., Miyahara H., Gotoh C., Choi K.C., Feng D.D., Chen C., Lee H.G., Katoh K., Roh S.G., and Sasaki S. Endocrinology 146 (2005) 5092
11. Ge H., Li X., Weiszmann J., Wang P., Baribault H., Chen J.-L., Tian H., and Li Y. Endocrinology 149 (2008) 4519
12. Carlson L.A. J. Intern. Med. 258 (2005) 94
13. 4) with 25 mM HEPES and 0.01% (w/v) BSA were stimulated with forskolin (5 μM final in 5 μl/well) in the presence of serially diluted test ligands (5 μl/well) in a 384-well Optiplate (Perkin-Elmer) at room temperature for 30 min before adding antibody and lysis reagents according to manufacturer's protocol. The plates were further incubated in the dark overnight after adding detection solution, and read in CLIPR (Molecular Devices) for 1 min per plate. Data were expressed as Relative Luminescence Unit (RLU).
14. Separated on ChiralPak AD-H column using 5% 2-propanol in hexanes. Retention times are 10.4 min for compound 3 and 13.8 min for compound 2.
15. 1H NMR and LC-MS.
16. Seebach D., Kolb M., and Grobel B.-T. Chem. Ber. 106 (1973) 2277-2290
17. Seebach D., Kolb M., and Grobel B.-T. Tetrahedron Lett. 36 (1974) 3171
18. Chamberlin A.R., Nguyen H.D., and Chung J.Y.L. J. Org. Chem. 49 (1984) 1682
19. Separated on ChiralCel OJ-H using 15% 2-propanol in hexanes. Retention times are 11.8 min for (S)-enantiomer 87 and 17.2 min for its (R)-enantiomer.
20. The chiral center was preserved under the coupling condition (step d in Scheme 1). The ee (enantiomeric excess) of 58 was determined to be >99%, by comparing to a mixture of S,R enantiomers (S/R = 3:1) that was obtained by running the same reaction using DBU (instead of 2,4,6-colidine) at room temperature. Retention times are 19.7 min for (S)-enantiomer 58 and 35.5 min for its (R)-enantiomer on ChiralPak AD-H using 5% 2-propanol in hexanes.
21. Lee T., Schwandner R., Swaminath G., Weiszmann J., Cardozo M., Greenberg J., Jaeckel P., Ge H., Wang Y., Jiao X., Liu J., Kayser F., Tian H., and Li Y. Mol. Pharmacol. 74 (2008) 1599
22. Swaminath, G.; Jaeckel, P.; Guo, Q.; Cardozo, M.; Weiszmann, J.; Lindberg, R.; Wang, Y.; Schwandner, R.; Li, Y., manuscript in preparation.
23. Langmead C.J., and Christopoulos A. Trends Pharmacol. Sci. 27 (2006) 475
24. May L.T., Leach K., Sexton P.M., and Christopoulos A. Annu. Rev. Pharmacol. Toxicol. 47 (2007) 1
25. Age-matched male FFA2 knockout (KO) or wild type (WT) mice (C57Bl/6 background) were used in the studies. Mice were fasted overnight before the experiment. Compound or vehicle alone (10% dimethyl acetamide, 10% ethanol, 30% propylene glycol, 50% saline) was intraperitoneally (ip) injected (10 ml/kg) into mice at indicated doses. Blood samples were collected before and 15 minutes after injection by tail bleeding. Plasma FFA levels were measured using a Wako HR Series FFA-HR (2) kit following manufacturers instructions.
26. At a high dose (20 mg/kg), however, compound 44 also reduced FFA levels in FFA2 KO mice, although to a lesser extent than in WT animals. This could be due to some off-target effects of compound 44, which was not extensively profiled against other targets. Compound 44 was inactive against a small panel of GPCRs that included FFA1, FFA3, GPR109A, GHSR, ETBR, CCR2, CXCR3, CXCR4, and CCR7 at concentrations up to 30 μM.
27. Cheng K., Wu T.-J., Wu K.K., Sturino C., Metters K., Gottesdiener K., Wright S.D., Wang Z., O'Neill G., Lai E., and Waters M.G. Proc. Natl. Acad. Sci. U.S.A. 103 (2006) 6682
28. Worm D., Henriksen J.E., Vaag A., Thye-Ronn P., Melander A., and Beck-Nielsen H. J. Clin. Endocrinol. Metab. 78 (1994) 717